吡格列酮对急性胰腺炎肝损伤的保护作用以及临床疗效研究

Protective effects of pioglitazone on IL-10 and liver injury in patients with acute pancreatitis

[目的]观察吡格列酮对急性胰腺炎(AP)患者的临床治疗作用,并探讨了其对患者肝损伤的保护作用。[方法]选取2014年7月~2016年11月我院住院治疗的AP患者116例,使用随机数字表法将患者分为观察组和对照组,每组58例。ELISA法检测丙氨酸转氨酶(ALT),天门氨酸氨基转移酶(AST),炎性因子:肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)、白介素-10(IL-10)。比较2组临床疗效和不良反应发生率。[结果]治疗前2组ALT和AST肝功能指标差异无统计学意义。治疗后观察组的ALT和AST均显著低于对照组(P<0.05)。治疗前2组炎性因子TNF-α、IL-6和IL-10比较,差异无统计学意义。治疗后观察组TNF-α和IL-6均显著低于对照组(P<0.05),观察组IL-10均显著高于对照组(P<0.05)。观察组的临床治疗有效率为91.4%(53/58),显著高于对照组的74.1%(43/58)(P<0.05)。观察组不良反应发生率为8.6%(5/58),对照组不良反应发生率为6.9%(4/58),差异无统计学意义。[结论]吡格列酮可抑制AP患者IL-10因子表达,阻止炎症反应,发挥肝损伤保护作用,临床疗效显著,使用安全。

[Objective]To detect the effects of pioglitazone on IL-10 and liver injury in patients with acute pancreatitis.[Methods]116 acute pancreatitis patients were enrolled in this study.Patients were divided into control group（n=48）and observation group（n=48）.ALT,AST,TNF-α,IL-6,and IL-10 expression were detected by ELISA analysis.The clinical effect and adverse reaction rate were compared between the two groups.[Results]Before treatment,there was no significant difference of ALT and AST between the two groups.After treatment,ALT and AST were lower in observation group than that in control group（P0.05）.Before treatment,there was no significant difference of TNF-α,IL-6,and IL-10 between the two groups.After treatment,TNF-αand IL-6,were lower in observation group than that in control group（P0.05）,and IL-10 was higher in observation group than that in control group（P0.05）.The clinical effect rate in observation was 91.4% （53/58）,which was higher than that of 74.1% （43/58）in control group（P0.05）.The rate of adverse reaction was 8.6% （5/58）in observation group and 6.9% （4/58）in control group,which has no significant difference.[Conclusion]Pioglitazone decreased IL-10 to inhibit inflammatory reaction and protect liver injury in patients with acute pancreatitis,with significantly clinical effect and safety.